15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $1M | -$7M | 48.7% | -585.8% | -112.5% | -81.4% | -$5M | $137000 | $405000 |
| 2024 | $1M | -$13M | 54.5% | -728.5% | -177.6% | -131.3% | -$5M | $140000 | $1M |
| 2023 | $911000 | -$12M | 48.5% | -1270.1% | -77.2% | -67.0% | -$7M | $144000 | $3M |
| 2022 | $397000 | -$15M | 48.9% | -3886.1% | -62.8% | -56.0% | -$8M | $147000 | $10M |
| 2021 | $898000 | -$9M | 12.6% | -971.5% | -26.9% | -24.6% | -$12M | $580000 | $15M |
| 2020 | $4M | -$7M | 2.8% | -168.6% | -27.6% | -25.2% | -$13M | $50000 | $7M |
| 2019 | $5M | -$4M | 2.6% | -90.8% | -12.2% | -11.9% | -$3M | — | $26M |
| 2018 | $2M | -$2M | 3.7% | -81.6% | -22.1% | -16.5% | -$2M | — | $2M |
| 2017 | $580372 | -$2M | 37.6% | -354.0% | -25.4% | -16.5% | -$2M | $452080 | $538000 |
| 2016 | $6M | -$3M | 13.2% | -45.6% | -20.8% | -14.9% | -$279887 | $829229 | $1M |
| 2015 | $8M | -$5M | 7.5% | -56.5% | -32.4% | -22.7% | -$3M | $2M | $824492 |
| 2014 | $2M | -$3M | 16.8% | -111.2% | -22.2% | -17.0% | -$2M | $0 | $1M |
| 2013 | $8M | -$2M | 19.1% | -30.9% | -15.6% | -11.7% | $238767 | — | $1M |
| 2012 | $4M | -$8M | -14.7% | -178.9% | -52.2% | -30.7% | -$5M | — | $562948 |
| 2011 | $4M | -$20M | 3.9% | -390.0% | -303.6% | -111.4% | -$3M | — | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $265000 | -$3M | 18.1% | -1050.6% | -47.9% | -30.9% | -$1M | — | $331000 |
| Mar '26 | $317000 | -$2M | 17.4% | -775.4% | -39.2% | -26.2% | -$1M | — | $207000 |
| Sep '25 | $191000 | -$2M | 51.8% | -1517.8% | -22.5% | -18.7% | — | $136000 | $1M |
| Jun '25 | $328000 | -$2M | 47.0% | -580.8% | -26.3% | -20.1% | -$1M | $136000 | $454000 |
| Mar '25 | $330000 | -$1M | 46.7% | -428.2% | -18.9% | -13.7% | -$748000 | $137000 | $405000 |
| Dec '24 | $257000 | -$2M | 40.5% | -730.7% | -29.2% | -20.1% | -$1M | $137000 | $470000 |
| Sep '24 | $412000 | -$2M | 48.1% | -427.2% | -23.3% | -16.6% | -$1M | $138000 | $2M |
| Jun '24 | $272000 | -$2M | 59.9% | -880.9% | -30.2% | -22.4% | -$2M | $139000 | $2M |
| Mar '24 | $295000 | -$3M | 58.0% | -735.6% | -39.4% | -29.1% | -$541000 | $140000 | $1M |
| Dec '23 | $204000 | -$6M | 65.2% | -1469.6% | -61.7% | -49.6% | -$2M | $141000 | $1M |
| Sep '23 | $291000 | -$2M | 59.8% | -856.0% | -17.4% | -14.8% | -$2M | $142000 | $3M |
| Jun '23 | $555000 | -$2M | 45.9% | -385.4% | -15.7% | -13.2% | -$1M | $143000 | $2M |
| Mar '23 | -$533000 | -$4M | -11.8% | 757.8% | -27.0% | -23.5% | — | $144000 | $3M |
| Dec '22 | $332000 | -$2M | 30.7% | -686.1% | -12.3% | -11.2% | — | $144000 | $5M |
| Sep '22 | $202000 | -$2M | 66.8% | -1231.7% | -12.1% | -11.1% | — | $145000 | $7M |
| Jun '22 | $212000 | -$3M | 67.0% | -1321.7% | -12.6% | -11.5% | -$2M | $146000 | $8M |
| Mar '22 | $122000 | -$7M | 55.7% | -5328.7% | -27.2% | -24.2% | -$942000 | $147000 | $10M |
| Dec '21 | $142000 | -$2M | 43.7% | -1679.6% | -8.1% | -7.6% | -$2M | $148000 | $12M |
| Sep '21 | $56000 | -$4M | 67.9% | -7764.3% | -13.9% | -12.8% | -$2M | $149000 | $14M |
| Jun '21 | $77000 | -$2M | 33.8% | -2849.4% | -5.6% | -5.2% | -$2M | $150000 | $13M |
How the market has priced IGC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, IGC Pharma, Inc.'s revenue has declined 20.8% per year. These are computed facts, not advice.
As of FY2025, IGC Pharma, Inc. reported $137000 of total debt against $405000 of cash.
In FY2025, gross margin was 48.7%, operating margin -585.8%, and net margin -560.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.